Microba Life Sciences (ASX:MAP) is named in a Takeovers Panel application filed by BCAL Diagnostics Limited (ASX:BDX) concerning a proposed merger between MAP and Genetic Signatures Limited (ASX:GSS), under which MAP shareholders would own 60% of the combined group and existing GSS shareholders would own 40%.
Key Points
- BCAL Diagnostics, holding 18.46% of GSS shares on issue, has lodged an application with the Takeovers Panel regarding the proposed GSS-MAP merger.
- Under revised terms announced on 21 October 2026, MAP shareholders would own 60% of the combined group and GSS shareholders would own 40%.
- The proposed transaction is to be implemented via a scheme of arrangement under which GSS would acquire 100% of MAP shares and options.
- The applicant seeks interim orders to restrain GSS from executing the scheme implementation deed without a fiduciary-out and to prevent Resolution 4 from being put to shareholders at the AGM.
- No sitting Panel has been appointed and no decision has been made on whether to conduct proceedings.
Background to the Proposed GSS-MAP Transaction
Genetic Signatures Limited announced on 26 August 2026 that it was in discussions with Microba Life Sciences in relation to a potential merger, noting at the time that the structure and commercial aspects of the proposed transaction were still being considered. On 22 September 2026, GSS announced that principal commercial terms had been agreed, with the transaction to be implemented by way of a scheme of arrangement under which GSS would acquire 100% of MAP shares and options. Under those initial terms, MAP shareholders were to own approximately 67% of the combined group and existing GSS shareholders approximately 33%.
Revised Merger Terms and AGM Notice Addendum
On 21 October 2026, GSS announced agreement in principle to revised terms under which MAP shareholders would own 60% of the combined group and GSS shareholders 40%. GSS also stated that an addendum to its notice of annual general meeting had been sent to the ASX for review. On 23 October 2026, GSS released the addendum, which introduced a new Resolution 4 seeking shareholder approval under ASX Listing Rule 7.1 for the issue of securities to MAP under the proposed transaction, and provided further details including a summary of the material terms of the proposed scheme implementation deed.
Grounds and Orders Sought by BCAL Diagnostics
BCAL Diagnostics submits that the proposed transaction is a control transaction for GSS without the protections of Chapter 6, and that deal protection arrangements disclosed in the addendum — specifically the absence of any fiduciary-out in favour of GSS and the GSS break fee — have the practical effect of precluding a competitive market for control of GSS. The applicant also submits that GSS shareholders have not been provided with sufficient time or information to make an informed assessment. Final orders sought include requiring a fiduciary-out in the scheme implementation deed, convening a separate general meeting, and commissioning an independent expert's report on the proposed transaction.




Please wait processing your request...